Arbutus Biopharma Corp expected to post a loss of 12 cents a share - Earnings Preview

Arbutus Biopharma

27/02/2024 12:33

* Arbutus Biopharma Corp  ABUS.OQ   ABUS.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
29 for the period ending December 31 2023
    * The Warminster Pennsylvania-based  company is expected to
report
a 23.2% decrease in revenue to $4.793 million from $6.25 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Arbutus Biopharma Corp
is for
a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arbutus
Biopharma
Corp is $4.00​, above​ its last closing price of $2.92. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.11       -0.11      -0.12     Missed  -5.4
 Jun. 30 2023  -0.11       -0.11      -0.10     Beat    10.9
 Mar. 31 2023  -0.14       -0.14      -0.10     Beat    26.5​
 Dec. 31 2022  -0.13       -0.13      -0.14     Missed  -5.2
 ​​Sep.        -0.13       -0.13      -0.12     Beat    6.3
 30 2022                                                
 Jun. 30 2022  -0.12       -0.13      -0.10     Beat    20.6​
 Mar. 31 2022  -0.15       -0.16      -0.11     Beat    31.3
 Dec. 31 2021  -0.19       -0.19      -0.15     Beat    21.1
 This summary was machine generated February 27 at 12:33 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)